Alkermes (ALKS) Other Non-Current Assets (2011 - 2026)

Alkermes' (ALKS) quarterly Other Non-Current Assets came in at $59.4 million in Q1 2026, up 223.14% year-on-year from $18.4 million in Q1 2025, and up 20.89% on a QoQ basis from $49.1 million in Q4 2025.

Alkermes (ALKS) Other Non-Current Assets (2011 - 2026) Analysis & Trends

Alkermes (ALKS) has 16 years of Other Non-Current Assets data on file, last reported at $59.4 million in Q1 2026.

  • On a quarterly basis, Other Non-Current Assets rose 223.14% year-over-year to $59.4 million in Q1 2026; TTM through Mar 2026 was $59.4 million, a 223.14% increase from a year earlier, with the FY2025 full-year figure at $49.1 million, up 197.52% from the prior year.
  • Other Non-Current Assets for Q1 2026 stood at $59.4 million, up from $49.1 million in the prior quarter.
  • Over the last five years, Other Non-Current Assets for ALKS reached as high as $59.4 million in Q1 2026 and fell as low as $10.7 million in Q1 2022.
  • Historically, Other Non-Current Assets has averaged $19.3 million across 5 years, with a median of $14.9 million in 2023.
  • Across the five-year window, Other Non-Current Assets sank 46.49% in 2022 and soared 223.14% in 2026, its largest moves.
  • Year by year, Other Non-Current Assets stood at $14.7 million in 2022, then dropped by 21.58% to $11.5 million in 2023, then jumped by 43.24% to $16.5 million in 2024, then surged by 197.52% to $49.1 million in 2025, then climbed by 20.89% to $59.4 million in 2026.
  • Per Business Quant data, the three most recent Other Non-Current Assets figures were $59.4 million in Q1 2026, $49.1 million in Q4 2025, and $19.7 million in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Other Non-Current Assets (Qtr)
1 Haleon 87.22 Bn 85.35 Bn - 49.22 Mn
2 Teva Pharmaceutical Industries 39.60 Bn 35.87 Bn 1.97 Bn 1.79 Bn
3 Zoetis 31.46 Bn 29.52 Bn 1.62 Bn 351.00 Mn
4 Takeda Pharmaceutical 26.49 Bn 22.44 Bn 4.39 Bn 491.06 Mn
5 United Therapeutics 23.03 Bn 20.88 Bn 648.10 Mn 233.20 Mn
6 Universe Pharmaceuticals 23.03 Bn -10.56 Bn - -
7 Viatris 20.90 Bn 19.09 Bn 1.16 Bn 1.11 Bn
8 Neurocrine Biosciences 17.50 Bn 16.19 Bn 800.70 Mn 73.60 Mn
9 Elanco Animal Health 12.33 Bn 11.91 Bn 785.00 Mn 295.00 Mn
10 Alkermes 9.72 Bn 9.21 Bn 331.33 Mn 59.36 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 59.36 Mn
Dec 31, 2025 49.10 Mn
Sep 30, 2025 19.66 Mn
Jun 30, 2025 19.91 Mn
Mar 31, 2025 18.37 Mn
Dec 31, 2024 16.50 Mn
Sep 30, 2024 16.80 Mn
Jun 30, 2024 16.30 Mn
Mar 31, 2024 11.52 Mn
Dec 31, 2023 11.52 Mn
Sep 30, 2023 11.29 Mn
Jun 30, 2023 14.54 Mn
Mar 31, 2023 14.91 Mn
Dec 31, 2022 14.69 Mn
Sep 30, 2022 10.98 Mn
Jun 30, 2022 11.57 Mn
Mar 31, 2022 10.66 Mn
Dec 31, 2021 27.46 Mn
Sep 30, 2021 16.77 Mn
Jun 30, 2021 17.40 Mn